JP2023524430A5 - - Google Patents

Info

Publication number
JP2023524430A5
JP2023524430A5 JP2022565760A JP2022565760A JP2023524430A5 JP 2023524430 A5 JP2023524430 A5 JP 2023524430A5 JP 2022565760 A JP2022565760 A JP 2022565760A JP 2022565760 A JP2022565760 A JP 2022565760A JP 2023524430 A5 JP2023524430 A5 JP 2023524430A5
Authority
JP
Japan
Prior art keywords
days
administration
immunomodulatory compound
cells
cell therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022565760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029503 external-priority patent/WO2021222330A2/en
Publication of JP2023524430A publication Critical patent/JP2023524430A/ja
Publication of JP2023524430A5 publication Critical patent/JP2023524430A5/ja
Pending legal-status Critical Current

Links

JP2022565760A 2020-04-28 2021-04-27 Bcma指向性t細胞療法と免疫調節化合物との併用 Pending JP2023524430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016983P 2020-04-28 2020-04-28
US63/016,983 2020-04-28
PCT/US2021/029503 WO2021222330A2 (en) 2020-04-28 2021-04-27 Combination of bcma-directed t cell therapy and an immunomodulatory compound

Publications (2)

Publication Number Publication Date
JP2023524430A JP2023524430A (ja) 2023-06-12
JP2023524430A5 true JP2023524430A5 (enExample) 2024-05-09

Family

ID=76502791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022565760A Pending JP2023524430A (ja) 2020-04-28 2021-04-27 Bcma指向性t細胞療法と免疫調節化合物との併用

Country Status (11)

Country Link
US (1) US20230165872A1 (enExample)
EP (1) EP4142723A2 (enExample)
JP (1) JP2023524430A (enExample)
KR (1) KR20230015921A (enExample)
CN (1) CN116157125A (enExample)
AU (1) AU2021263765A1 (enExample)
BR (1) BR112022021788A2 (enExample)
CA (1) CA3181399A1 (enExample)
IL (1) IL297688A (enExample)
MX (1) MX2022013530A (enExample)
WO (1) WO2021222330A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN118201618A (zh) * 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
CA3233953A1 (en) * 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025137751A1 (pt) * 2023-12-26 2025-07-03 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Polinucleotídeo, receptor de antígeno quimérico, vetor, composição, método para produção de célula imune efetora modificada e uso do polinucleotídeo

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7204296B2 (en) 2004-07-26 2007-04-17 Metal Casting Technology, Incorporated Method of removing a fugitive pattern from a mold
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
PL3198345T3 (pl) 2014-09-22 2021-08-23 Sacmi Cooperativa Meccanici Imola Societa' Cooperativa Linia do produkcji pojedynczych wyrobów w następujących po sobie w cyklu ciągłym
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
WO2018085690A1 (en) * 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
EP4467143B1 (en) * 2017-07-10 2026-03-11 Celgene Corporation Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
SG11202000606TA (en) 2017-07-29 2020-02-27 Juno Therapeutics Inc Reagents for expanding cells expressing recombinant receptors
PT3703750T (pt) * 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
PL3796912T3 (pl) * 2018-05-23 2023-09-11 Celgene Corporation Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego
MA54078A (fr) * 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
CA3117978A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
CN113747896A (zh) * 2019-04-22 2021-12-03 斯塔顿治疗公司 来那度胺和其他免疫调节剂的连续递送
IL292667B1 (en) * 2019-11-07 2026-02-01 Juno Therapeutics Inc Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione

Similar Documents

Publication Publication Date Title
JP2023524430A5 (enExample)
US20250262318A1 (en) Methods and pharmaceutical composition for the treatment of cancer
AU2018203924B2 (en) Toxicity management for anti-tumor activity of cars
AU2017302668B9 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
KR102717188B1 (ko) 암의 치료를 위한 키메라 항원 수용체
TWI750110B (zh) 使用人類化抗-bcma嵌合抗原受體治療癌症
US20200055948A1 (en) Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
JP2022512971A5 (enExample)
US20220175725A1 (en) Combination of immunotherapies with mdm2 inhibitors
JP2024540275A5 (enExample)
JP2021512107A5 (enExample)
JP2022529059A (ja) バリアントicosリガンド(icosl)融合タンパク質の方法および使用
JP2024513054A5 (enExample)
TW202208419A (zh) 靶向愛潑斯坦巴爾病毒的tcr-t細胞療法
JP2022554353A5 (enExample)
JP2024514163A5 (enExample)
JP2024540320A5 (enExample)
WO2021222552A1 (en) Methods of treating cytokine-related adverse events
RU2809160C2 (ru) Виды комбинированной терапии с использованием химерных антигенных рецепторов и ингибиторов pd-1
Ying et al. Advances in Immunotherapy for Multiple Myeloma
HK40116181B (en) Toxicity management for anti-tumor activity of cars
HK40039113A (en) Toxicity management for anti-tumor activity of cars
RU2021118587A (ru) Антитела, специфичные в отношении нектина-2 человека
RU2019138707A (ru) Сочетание клеточной терапии и иммуномодуляторного соединения